Tvardi Therapeutics, Inc. (TVRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.74M
Last updated: Nov 17, 2026 at 11:04 AM ET
Tvardi Therapeutics, Inc. (TVRD) Competitors
The companies most similar to Tvardi Therapeutics are Tscan Therapeutics (TCRX), Plus Therapeutics (PSTV) and Marker Therapeutics (MRKR). By market cap, Tvardi Therapeutics ranks 4th of the 13 companies on this page; Plus Therapeutics (PSTV) is the largest at $26.64M.
Peer Comparison
TVRD's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics (TVRD) | $15.74M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tscan Therapeutics Inc (TCRX) | $10.89M | N/A | 3.6x | 0.0% | -129.7% | -65.8% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Transcode Therapeutics Inc (RNAZ) | $22.35M | N/A | N/A | 0.0% | -412.7% | 0.0% | 0.00% |
| Intensity Therapeutics, Inc. Common stock (INTS) | $10.17M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Biovie Inc (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Vyne Therapeutics Inc (VYNE) | $19.07M | N/A | N/A | 0.0% | N/A | -57.4% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Seres Therapeutics Inc (MCRB) | $14.27M | N/A | 6.6x | 0.0% | N/A | 68.9% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| Quantum BioPharma Ltd. (QNTM) | $10.35M | N/A | N/A | 0.0% | -150.1% | 0.0% | 0.00% |
| Peer median | $13.20M | N/A | 7.7x | 0.0% | -281.4% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Tvardi Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Tscan Therapeutics Inc (TCRX) | Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor... | TCRX competitors |
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Transcode Therapeutics Inc (RNAZ) | TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic... | RNAZ competitors |
| Intensity Therapeutics, Inc. Common stock (INTS) | Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. | INTS competitors |
| Biovie Inc (BIVI) | BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. | BIVI competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Vyne Therapeutics Inc (VYNE) | VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. | |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Seres Therapeutics Inc (MCRB) | Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally... | MCRB competitors |
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
| Quantum BioPharma Ltd. (QNTM) | Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases. | QNTM competitors |
Frequently Asked Questions About TVRD
Who are Tvardi Therapeutics' main competitors?
The companies most similar to Tvardi Therapeutics include Tscan Therapeutics (TCRX), Plus Therapeutics (PSTV), Marker Therapeutics (MRKR), Transcode Therapeutics (RNAZ) and Intensity Therapeutics, Inc. Common stock (INTS), listed from the closest match.
Who is Tvardi Therapeutics' biggest competitor?
Plus Therapeutics (PSTV) is the largest of the similar companies at $26.64M; Tscan Therapeutics (TCRX) is the closest match by business profile, size, sector and industry.
How does TVRD stock compare with its competitors?
TVRD's net margin is 0.0% against a peer median of 0.0%.
Which of Tvardi Therapeutics' competitors pays a higher dividend?
Tvardi Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Tvardi Therapeutics bigger than its competitors?
No. Tvardi Therapeutics is 4th by market cap among the 13 companies on this page; the largest is Plus Therapeutics (PSTV) at $26.64M.
TVRD pages: Overview, Earnings, Forecast, Financials, Competitors